Federation des caisses Desjardins du Quebec’s Monopar Therapeutics MNPR Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16	Closed	-$583	–	2799
2025 Q1	$583	Hold	16	–	–	﹤0.01%	2474
2024 Q4	$352	Hold	16	–	–	﹤0.01%	2421
2024 Q3	$108	Hold	16	–	–	﹤0.01%	2489
2024 Q2	$58	Hold	16	–	–	﹤0.01%	2413
2024 Q1	$54	Hold	16	–	–	﹤0.01%	2359
2023 Q4	$27	Hold	16	–	–	﹤0.01%	2347
2023 Q3	$50	Buy	+16	New	+$56	﹤0.01%	2346

Other funds holding MNPR

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's MNPR Position: Q2 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Monopar Therapeutics (MNPR) in Q2 2025, closing a stake of 16 shares — an estimated $583 sold.

Federation des caisses Desjardins du Quebec first reported a position in MNPR in Q3 2023 and held it in 7 quarters. The position peaked at $583 in Q1 2025. 43 funds tracked by Wall St. Rank hold MNPR as of Q2 2025.

Federation des caisses Desjardins du Quebec reported no remaining Monopar Therapeutics position as of Q2 2025 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 16 Monopar Therapeutics shares in Q2 2025, an estimated $583.
Federation des caisses Desjardins du Quebec first reported a position in Monopar Therapeutics in Q3 2023 and held it in 7 quarters.
Federation des caisses Desjardins du Quebec's Monopar Therapeutics position peaked at $583 in Q1 2025.
43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2025, filed 14 Aug 2025.